Neurocognition After Perturbed Sleep

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-21

Study Completion Date

2024-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Individuals with schizophrenia display a wide range of neurocognitive difficulties resulting in functional impairment and disability. Extensive evidence indicates insomnia and sleep disturbances play a substantial role in degrading cognitive functioning. However, the putative impact of insomnia and sleep disturbances on neurocognition and daily functioning has not been investigated in people with schizophrenia. The goal of this study is to characterize sleep in individuals with schizophrenia and quantify its impact on neurocognition and daily functioning.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sleep in Psychiatric Inpatients

NCT04201392

Sleep Disturbance Sleep Disorder Insomnia +2 more

UNKNOWN

Neurobehavioral Effects of Partial Sleep Deprivation

NCT02128737

Control 1 Night Recovery Sleep 3 Nights Recovery Sleep +1 more

COMPLETED NA

The Effect of Sleep Loss on Emotion Regulation

NCT05393830

Sleep Insomnia Sleep Deprivation

RECRUITING NA

Neural Mechanisms Underlying the Antidepressant Effects of Sleep Deprivation

NCT03169543

Depression, Unipolar

COMPLETED NA

Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease

NCT03256539

Sleep Alzheimer Disease Cognitive Impairment +2 more

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Individuals with SZ display a broad range of neurocognitive difficulties that have been identified as major determinants of poor functioning and disability, thus representing an important public health concern and a focal target for interventions. Extensive research literatures converge in highlighting the critical role insomnia and sleep disturbances play in degrading neurocognitive functioning. Such sleep disturbances result in clinical presentations similar to neurocognitive difficulties commonly observed in people with SZ. While insomnia and sleep disturbances are highly prevalent in people with SZ, there are scant data on the impact of sleep disturbances on neurocognition in SZ, and no data quantifying their influence on daily functioning. Thus, sleep disturbances remain poorly understood and modeled in SZ, their impact is rarely considered in clinical trials, and they remain largely unaddressed by clinicians. To address this gap in knowledge, the primary aim of this study is to characterize sleep in individuals with SZ and quantify its impact on neurocognition and daily functioning. Employing an experimental, within-person, repeated assessment design, the study team will characterize sleep architecture, duration, and quality along with cognitive, electrophysiological, biomarkers and daily functioning sequelae in 40 individuals with SZ. Participants will first complete a week-long, in-home characterization of sleep duration and quality using actigraphy and a sleep diary. Next, they will complete two overnight polysomnography examinations employing two sleep schedules:

1\) undisturbed sleep; and 2) restricted sleep (4 hours). As part of these assessments, participants will provide blood samples for biomarkers analyses and complete EEG-indexed memory tasks pre- and post-sleep, along with a post-sleep battery of neurocognitive functioning.

Finally, participants will complete a 3-day ambulatory assessment using actigraphy and smartphones to explore the impact of each sleep schedule on "real-world" daily functioning including symptoms, emotion regulation, and mood.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Outcome Assessors

The neurocognitive evaluators who administer the neurocognitive battery (MCCB) will be blinded to sleep schedule.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Undisturbed Sleep

8 hours sleep - Subjects randomized to the undisturbed sleep will be instructed to go to sleep at 11pm, and awoken at 7am.

Group Type ACTIVE_COMPARATOR

Overnight polysomnography examinations

Intervention Type BEHAVIORAL

sleep lab for overnight polysomnography examinations

Restricted Sleep

4 hours sleep - Subjects randomized to the restricted sleep will be instructed to go to sleep at 3am and awoken at 7am.

Group Type EXPERIMENTAL

Overnight polysomnography examinations

Intervention Type BEHAVIORAL

sleep lab for overnight polysomnography examinations

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Overnight polysomnography examinations

sleep lab for overnight polysomnography examinations

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Females or males age 18-60 years
* DSM-5 diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder
* Taking antipsychotic medication for \>7 weeks and on current doses for 4 weeks, and/or injectable depot antipsychotics with no change in the last 3 months
* Capacity to understand all the potential risks and benefits of the study.

Exclusion Criteria

* DSM-5 alcohol/substance diagnosis (except nicotine) within the last 6 months
* Taking medications affecting sleep propensity or architecture (other than antipsychotic medication)
* Initiation of medications known to impact cognition in previous 4 weeks or any change in doses during this period
* History of seizures/head trauma with loss of consciousness (\>10 min) resulting in cognitive sequelae
* Medical or neurological conditions that could interfere with participation (e.g., untreated hypothyroidism
* Mental retardation
* Narcolepsy
* REM behavior disorder, parasomnias)
* Pregnant/ nursing
* Serious homicidal/suicidal risk (past 6 months)
* Moderate or more severe disorganization (PANSS≥4)
* Poor English reading ability (WTAR\<7)
* Individuals employed as vehicle drivers/train operators or have occupations in which lapses in sustained vigilance would compromise safety
* Night shift workers or those with irregular sleep-wake rhythms (based on the week-long home actigraphy; i.e., average bedtime of 11pm±2 hours)
* Participation in the past 3 months in cognition study

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No